Combination studies with other oncolytic virus include NCT02272855 trial, which will analyze CTLA-4 ICKB with HF10, an oncolytic virus that has shown to induce angiogenesis and affluence of CD8+ T-cells at the tumor microenvironment (64). The gene discussed is CD8A; the disease is neoplasm.